The International Myeloma Foundation (IMF) reports that pomalidomide and carfilzomib “are both moving closer to approval for patients who have relapsed or do not respond to current drugs.” in their summer addition of Myeloma Today.
The story, which was buried at the bottom of their “News & Notes” section, goes on to add that “The pomalidomide phase II clinical trial data continues to mature, demonstrating the best overall response rate to date, and accelerated filing strategies in the U.S. are under discussion.”
All I can say is: It’s about time! The drug’s developer, Celgene, is a large corporation that is very deliberate in it’s approach. Pomalidomide is probably the most promising anti-myeloma drug under development today. It would be great if Celgene would push harder for FDA approval, like Onyx Pharmaceuticals is doing with carfilzomib, the second most promising new anti-myeloma drug.
Onyx is in the process of applying to the FDA for something called accelerated approval. According to company spokesmen, FDA approval could be granted as early as the end of this year.
Are you interested in following the progress of pomalidomide and carfilzomib, along with dozens of other new, promising anti-myeloma compounds being developed around the world? Don’t forget to check MyelomaNews.com for links to news releases about pre-clinical and early clinical trials that I don’t have room to report about here.
There is a lot to be hopeful about for myeloma patients these days. Hopefully my recent stem cell transplant will buy me enough time to take advantage of the new experimental combination therapy approaches that are only two or three years away.
Feel good and keep smiling! Pat